AxoGen Stock News

Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which be

AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to sup

ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript

ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi

ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the be

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for ne

ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves,

AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement

ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves,

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi

AxoGen (NASDAQ:AXGN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports. Several other research a

Canaccord Genuity analyst Kyle Rose maintained a Hold rating on AxoGen (AXGN – Research Report) on October 11 and set

COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.